BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9865827)

  • 1. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIB-1 staining index of pediatric meningiomas.
    Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
    Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.
    Prayson RA
    Am J Clin Pathol; 1996 Jun; 105(6):719-26. PubMed ID: 8659446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
    Devaprasath A; Chacko G
    Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
    Hsu DW; Efird JT; Hedley-Whyte ET
    Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
    Schiffer D; Ghimenti C; Fiano V
    J Neurooncol; 2005 Jun; 73(2):125-30. PubMed ID: 15981101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
    Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
    Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
    Vankalakunti M; Vasishta RK; Das Radotra B; Khosla VK
    Neuropathology; 2007 Oct; 27(5):407-12. PubMed ID: 18018472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
    Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
    J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
    Abry E; Thomassen IØ; Salvesen ØO; Torp SH
    Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical and malignant meningiomas: a clinicopathological review.
    Mahmood A; Caccamo DV; Tomecek FJ; Malik GM
    Neurosurgery; 1993 Dec; 33(6):955-63. PubMed ID: 8134008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic features predicting recurrence of meningiomas following subtotal resection.
    de la Monte SM; Flickinger J; Linggood RM
    Am J Surg Pathol; 1986 Dec; 10(12):836-43. PubMed ID: 3789250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.